The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Used to trade Standard Life shares before the merger which I didn’t like. Now it seems Standard Life name and everything else to be dumped and back to dodgy Aberdeen now?. No thanks
I’m growing my rights issue shares to recover my original stake. Anybody else doing this?. Sitting on sidelines with cash at moment but could get around 1985 shares if I bought
Shares/ buy/sell
1530 / 84.8 / 176.98 RI
1917 / 140.66 / 158.98
I sold my GSK at 1383 and AZN at 4345 in July 2015. Since then GSK are around 9% down and AZN are 67% up. I know about dividends paid. What the ... happened?
Don’t know if this been posted, target price 1150. Shares now at year low 1267. Looking to buy into a few shares for the dividend in the Spring and maybe GSK.
DEUTSCHE BANK CUTS GLAXOSMITHKLINE TO 'SELL', SAYS VALUATION ALONE IS NOT ENOUGH
(Sharecast News) - Analysts at Deutsche Bank downgraded their recommendation for shares of GlaxoSmithKline to "sell" following the UK drug giant's latest quarterly update.
In a research note sent to clients, they explained that GSK's fourth quarter financials and outlook had been weaker than their already cautious stance.
Deutsche had previously had the shares at 'hold'. The broker also cut its target price on the stock from 1,400.0p to 1,150.0p.
A further proviso was that valuation was not enough to justify an investment and in any case offered limited support, given how shares in several of GSK's large global peers were also trading on single digit valuation multiples.
In order to be just "vaguely constuctive", one one need to believe that growth was set to rebound in 2022 and that the risk-reward trade-off around the catalyst for the firm's interim research and development pipeline was "attractive".
Deutsche said its confidence was "limited" on both fronts.
"2022 confidence relies on growth being deferred rather than lost, which is non-obvious (we can easily envisage a scenario in which pandemic disruption sees launches/Shingrix constrained into 2022 [...])."
Not looked at this for 5 years. Why is still same price as then?
Nearer 24% drop
??
Sharecast News) - Provident Financial said it was on course to meet market expectations for 2020 but that Covid-19 lockdowns would hit customer spending and borrowing.
The subprime lender said trading in the third quarter was in line with management forecasts. It has ordered an operational review of its consumer credit division (CDD), which includes its main doorstep lending business.
Delinquency trends at the Vanquis credit card business were stable but customer booking volumes were lower than a year earlier. Customer spending at Vanquis was 31% up on the previous quarter but 15% lower than a year earlier.
Home credit lending to existing customers was more than 70% of normalised levels for the third quarter and loans to new customers were at about 60%, the FTSE 250 company said. The consumer credit business, which also includes online loans, has been hit by Covid-19, stricter rules and a rise in customer complaints.
Chief Executive Malcolm Le May said: "We remain vigilant for possible economic shocks, including those caused by further local and national lockdowns. Such measures will inevitably have an impact on customer expenditure patterns and loan origination.
"I have asked the new managing director of CCD, Hamish Paton, to undertake an operational review of the division. This will ensure that the business is best positioned, in the context of these industry dynamics, to return to delivering long-term sustainable profitability, whilst continuing to focus on good customer outcomes."
Le May said Provident had £700m of regulatory capital at the end of September - £200m more than the regulatory minimum.
Provident shares rose 2.9% to 240.20p at 08:28 GMT.
From notification I got:
Please note that the book cost applied to the credit of New IAG shares is the amount you have paid plus the book cost that was originally apportioned to the Rights which you have exercised. The Cost Per Share for the credit of New shares will therefore show as the total book cost applied to the credit, divided by the number of shares received. The cash amount you paid per New share was 84.74 pence.